• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA

by last | Dec 13, 2016 | 2016, Press Releases

PR_Philogen_13_12_2016

Philogen S.p.A. announces participation in the “World Immunotherapy Congress 2016”, 14 – 16 November 2016, Basel, Switzerland

by last | Nov 1, 2016 | 2016, Press Releases

Press_release_1_November_2016

Philogen S.p.A announces participation in “PEGS Europe – Protein & Antibody Engineering Summit” , 31 October – 4 November 2016, Lisbon, Portugal

by last | Oct 31, 2016 | 2016, Press Releases

PR Philogen 31 October 2016

Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

by last | Oct 28, 2016 | 2016, Press Releases

PR Philogen 281016

Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”, 28 August – 1 September 2016, Manchester, UK

by last | Aug 11, 2016 | 2016, Press Releases

Press release_Philogen 11 August 2016

Philogen S.p.A. announced that they have entered into a collaboration

by last | Aug 3, 2016 | 2016, Press Releases

Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics....
« Older Entries

Recent Posts

  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
  • Philochem will be attending the 10th World ADC Conference in London
  • Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
  • Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch